



Review

Nitroergic Enteric Neurons in Health and Disease—Focus on Animal Models

Nikolett Bódi *, Zita Szalai and Mária Bagyánszki 

Department of Physiology, Anatomy and Neuroscience, Faculty of Science and Informatics, University of Szeged, H-6726 Szeged, Hungary; zszalai@bio.u-szeged.hu (Z.S.); bmarcsi@bio.u-szeged.hu (M.B.)

* Correspondence: bodi.nikolett@bio.u-szeged.hu

Received: 28 March 2019; Accepted: 18 April 2019; Published: 24 April 2019



Abstract: Nitroergic enteric neurons are key players of the descending inhibitory reflex of intestinal peristalsis, therefore loss or damage of these neurons can contribute to developing gastrointestinal motility disturbances suffered by patients worldwide. There is accumulating evidence that the vulnerability of nitroergic enteric neurons to neuropathy is strictly region-specific and that the two main enteric plexuses display different nitroergic neuronal damage. Alterations both in the proportion of the nitroergic subpopulation and in the total number of enteric neurons suggest that modification of the neurochemical character or neuronal death occurs in the investigated gut segments. This review aims to summarize the gastrointestinal region and/or plexus-dependent pathological changes in the number of nitric oxide synthase (NOS)-containing neurons, the NO release and the cellular and subcellular expression of different NOS isoforms. Additionally, some of the underlying mechanisms associated with the nitroergic pathway in the background of different diseases, e.g., type 1 diabetes, chronic alcoholism, intestinal inflammation or ischaemia, will be discussed.

Keywords: nitric oxide synthase; nitroergic enteric neurons; enteric plexuses; microbiota–gut–brain axis; type 1 diabetes; alcoholism; gastrointestinal inflammation

1. Introduction

In the gastrointestinal (GI) tract, as in most other organ systems, nitric oxide (NO) plays a defining role in regulating several functions in both physiological and pathological states. NO contributes to the maintenance of GI mucosal integrity and circulation, regulation of secretion, smooth muscle function or mucosal inflammation [1,2]. NO, produced by neuronal NO synthase (nNOS), is one of the main inhibitory neurotransmitters in GI smooth muscle [3,4].

The involvement of nNOS and NO pathways in enteric neuropathies was well-described in a variety of disorders, like esophageal or internal anal sphincter achalasia, hypertrophic pyloric stenosis, gastroparesis, Chagas', or Hirschsprung's disease [5]. This review will provide information about the role of enteric neuronal NO in health and different pathological animal models with type 1 diabetes, chronic alcoholism, intestinal inflammation, or ischaemia.

2. Enteric Neurons

Enteric neurons reside in two ganglionated plexuses of the enteric nervous system (ENS). The myenteric plexus is situated between the longitudinal and circular muscle layers of the gut tube and regulates the motility of these smooth muscles. The submucous plexus is embedded in the GI submucosal layer and coordinates the absorption, secretion and circulation of the gut wall [6]. The enteric ganglia (Figure 1) contains enteric glia cells and neurons, connected by interganglionic

segments. The number of enteric neurons is equal to the number of spinal cord neurons in the same species [7].




Figure 1. Representative fluorescent micrograph of a myenteric (a) and a submucous (b) ganglion from the duodenum of a control rat after peripherin immunolabelling. The myenteric ganglion (a) is bigger and contains more neurons than the submucous (b) one. Arrows show the immunolabelled neuronal processes in the submucous plexus. Scale bars: 20 μ m.

Intrinsic primary sensory neurons, interneurons and motoneurons are all present in the ENS, therefore the enteric neurons are able to form local reflex circuits in the intestinal wall and can work autonomously from the central nervous system [6,8]. At the same time, the ENS bidirectionally communicates with the central nervous system [9,10], and several data support the intimate connection of ENS and gut microbiota, therefore these three systems make a microbiota–gut–brain axis [11,12].

The neurochemical phenotype of enteric neurons is critical to their function [13,14]. The neurochemical composition of the ENS is much more diverse than the sympathetic and parasympathetic divisions of the autonomic nervous system. From this point of view, the ENS is similar to the central nervous system, since the whole range of the classical and other neurotransmitters are present in enteric neurons [13,15].

Nitroergic Enteric Neurons

NO can be synthesized by nNOS, endothelial NOS (eNOS) and inducible NOS (iNOS) in the different cell types in the body. In the ENS, the major inhibitory non-adrenergic, non-cholinergic (NANC) neurotransmitter is endogenous NO [4,16–18]. In enteric neurons, nNOS is the predominant form that produces NO in a physiological state [14,19–22], but all three isoforms of the NOS are present in mRNA and protein levels (Figure 2) in the enteric neurons. Different pathological states might affect the role of the NOS isoforms in the ENS [23].

The proportion of the nitroergic subpopulation when compared to the total neuronal cell number is shown to be different in the two enteric plexuses. The nitroergic neurons account for only a few percent of all neurons in the submucous plexus [24], while the proportion of the nitroergic myenteric neurons (Figure 3) is significant (23–52%). This massive proportion of the nitroergic myenteric neurons can be explained by the function of this neuron population. Most of the nitroergic myenteric neurons are inhibitory interneurons or inhibitory motoneurons innervating the muscle layers of the alimentary tract [14,25].




Figure 2. Representative transmission electron micrographs of myenteric ganglia from the duodenum of a control rat after post-embedding immunohistochemistry, using a nNOS (a), eNOS (b) and iNOS (c)-specific antibody. Circles show the 18 nm gold particles conjugated to different NOS isoforms. Scale bars: 200 nm.




Figure 3. Representative fluorescent micrograph of myenteric neurons from the duodenum of a control rat after nNOS (green)-HuCD (red) double labelling. Stars indicate neurons that are labelled for HuCD only, arrows point to neurons that are double-labelled for both nNOS and HuCD. Scale bar: 50 μ m.

3. Pathophysiology of Nitroergic Enteric Neurons

3.1. Type 1 Diabetes

It is well established that NOS-containing myenteric neurons are curiously susceptible to diabetic injuries [26–28] and impaired nitroergic innervation is accompanied by motility dysfunction [29]. Moreover, the nitroergic neurons located in different gut segments display strictly region-specific responsiveness to the diabetic state and also to immediate insulin replacement [27]. In the jejunum, ileum and colon of diabetic rats, both the nitroergic and total number of myenteric neurons were decreased assuming diabetes-related cell loss in these segments. However, in the duodenum of diabetic rats, the decreased number of nitroergic neurons was not accompanied by changes in the total number of myenteric neurons, presuming region-specific neurochemical modification of neurons here [27] (Table 1). Several other studies confirm diabetes-associated decreases of nitroergic myenteric neurons. nNOS neurons are reduced in the antrum and jejunum in spontaneously diabetic Bio-breeding rats [28], in the ileum of diabetic dogs [30], and in the human appendix [31], and reduced nNOS protein and mRNA expression were observed in the stomach of mice [29,32] with P2×7 receptor-mediated diabetic damage of nitroergic neurons [32]. Besides nitroergic neuronal damage, the diabetic animals represented delayed gastric emptying [29] and faster small intestinal and colonic transit compared to controls [27,33].

Table 1. Alterations in the number of nitroergic and total myenteric neurons and their consequences in different intestinal regions of rats with type 1 diabetes or chronic alcohol consumption. The number of total and nitroergic neurons varied differently dependent on the gut segment and also the type of disease. The number of nitroergic myenteric neurons decreased in all investigated gut segments of diabetic rats and also ethanol-treated animals. In diabetic rats, with the exception of the duodenum, the total neuronal number was also decreased in the other intestinal regions; suggesting enteric neuronal loss in these segments and neurochemical modification in the duodenum. In ethanol-treated rats, the total number of myenteric neurons was not affected in the different gut segments proposing modification of nNOS production in neurons. Summarized from Izbéki et al. [27] and Krecsmarik et al. [34].

Animal Models	Number of Myenteric Neurons	Duodenum	Jejunum	Ileum	Colon
Type 1 Diabetes [27]	Nitroergic	↓	↓	↓	↓
	Total	∅	↓	↓	↓
	Pathological alteration in nitroergic myenteric neurons	neurochemical modification	neuronal loss	neuronal loss	neuronal loss
Chronic Alcohol Consumption [34]	Nitroergic	↓	↓	↓	↓
	Total	∅	∅	∅	∅
	Pathological alteration in nitroergic myenteric neurons	neurochemical modification	neurochemical modification	neurochemical modification	neurochemical modification

In the submucous plexus, the proportion of nNOS-immunoreactive neurons was doubled in the ileum and tripled in the colon, but not in the duodenum of diabetic rats, while the total neuronal number remained unchanged, suggesting neurochemical adaptation of submucous neurons [35]. These results emphasize that the diabetic state affects the two enteric plexuses differentially.

In addition, in the microenvironment of enteric neurons, the number of eNOS-labelling gold particles was increased in the capillary endothelium of different gut segments [36], suggesting that the microvessels supplying to the myenteric ganglia are targets of diabetic damage in a regional manner and may contribute to developing neuropathy in diabetes.

Sex dependency on the diabetic nitroergic dysfunction was also observed [37]; females seem to have greater vulnerability to diabetes-related gastric impairments than males [38]. A decreased level of tetrahydrobiopterin, a major cofactor for NO synthesis, contributes to delayed gastric emptying, reduced pyloric nitroergic relaxation and nNOS- α protein expression in female diabetic rats [39].

NOS-containing neurons go through a two-phase degeneration process. The decrease in axonal nNOS expression as the hallmark of the first phase is reversible, however, causing irreversible changes, as apoptotic loss of nitrergic neurons occurs in the second one [26,40]. In addition, progressive accumulation of advanced glycation end products (AGEs) during diabetes seems to enhance this apoptotic process [41]. AGEs significantly reduce the expression of nNOS and NO release in myenteric neurons via their receptor [42]. Prevention of AGE formation by certain drugs precedes the decrease of nNOS in diabetic rats [43] and may also help to protect against nitrergic nerve dysfunction. Furthermore, the endogenous antioxidant defense of the gut can also be protective for nitrergic myenteric neurons. An extensive increase in the ratio of nNOS-immunoreactive neurons colocalizing with heme oxygenases was revealed in the ileum and colon of diabetic rats, though the nitrergic neuronal number decreased [44], suggesting that those NOS neurons which do not colocalize with heme oxygenases are the most damaged by diabetes [44,45].

3.2. Chronic Alcohol Consumption

The impact of chronic ethanol intake on NOS-immunoreactive myenteric neurons in various gut regions has been investigated in our laboratory for more than a decade. The number of nNOS-immunoreactive neurons was significantly reduced in all investigated intestinal regions after 8 weeks of ethanol consumption [34]. Since the total neuronal number in the myenteric ganglia remained unchanged, the alteration in the number of nNOS-immunoreactive neurons means that ethanol treatment specifically affected nNOS production (Table 1), damaging NO pathways in the ENS and disturbing gastrointestinal motility [46]. A decreased number of nNOS-immunoreactive neurons was also described in the murine jejunum after alcohol intake, but because it is accompanied by an increased proportion of iNOS-immunoreactive neurons [47], the number of NO-producing neurons remained constant. This data proposed a compensatory mechanism to restore the NOS balance. However, using bio-imaging of individual myenteric neurons, the basal NO synthesis was significantly enhanced after chronic alcohol consumption. Bio-imaging recordings also strengthened the elevated NO synthesis in the enteric glial cells, smooth muscle cells and endothelial cells, indicating a general increase in NO production in the intestinal wall [23]. In cultures, NO facilitates the protective effects of neuronal growth factors and helps with developing neurons to resist alcohol toxicity by activating the NO-cGMP-PKG-NFkappaB signalling pathway [48,49].

Similarly, electron microscopic study of the distribution of different NOS enzymes after ethanol treatment revealed opposite changes in the quantity of nNOS- and eNOS-labelling gold particles not only in the myenteric ganglia, but also in their close microenvironment [18]. While the number of nNOS labels has fallen by more than half, eNOS labels almost doubled in the duodenal ganglia, suggesting possible functional plasticity between NOS isoforms that might help to maintain the optimum NO level during chronic alcohol consumption. Moreover, gut segment-specific rearrangement of NOS isoforms in the various subcellular compartments was detected in rats after ethanol treatment [18].

3.3. Intestinal Inflammation

Although impairments of enteric neurons in different inflammatory diseases have been widely studied [50–55], there are numerous open questions and no consensus on how the ENS is affected in these inflammatory disorders. Intestinal inflammation affects not only the density of enteric neurons but also their function [56,57].

Extensive damage of myenteric neurons as a distinct early event was demonstrated in the inflamed colonic segment in different rat models despite the sustained inflammatory processes [50,58]. The rapid influx of activated immune cells after the onset of colitis accompanied elevated NO production from enhanced iNOS expression, which can be cytotoxic to enteric neurons. The immune-cell-mediated neuronal loss could be blocked by iNOS inhibitors [59]. Glial cells can also enhance iNOS activity during inflammation [60]. Brown et al. [61] observed the enhancement of glial NO levels and increased immunoreactivity of nitrated proteins (another marker of NO concentration) colocalized with glial

fibrillar acidic protein 48 h after the induction of colitis. Elevated nitric oxide facilitates the release of glial adenosine triphosphate and assists with neuronal loss [61].

Among the different subpopulations of enteric neurons, the vasoactive intestinal polypeptide (VIP)-positive and nitrenergic neurons display contrary responses to gut inflammation. In the inflamed colonic regions, the number of NOS neurons increased and the percentage of VIP neurons was unchanged in the myenteric plexus of paediatric patients with Crohn's disease [52]. However, in the submucous ganglia, an increased number of VIP-immunoreactive neurons was observed, while the number of NOS neurons was too low for quantification [52]. The regulation of nNOS expression seems different in models of Crohn's disease and ulcerative colitis. In 2,4,6-trinitrobenzenesulfonic acid-induced Crohn's disease, decreased nNOS protein and mRNA level was measured, but nNOS levels were not altered in experimentally-induced ulcerative colitis [53]. The proportion of nNOS-immunoreactive myenteric neurons was decreased in a stress-induced rat model of irritable bowel syndrome with diarrhea [54] contributing to the motility dysfunction characteristic for this disease.

The activity of NOS and the generation of NO were elevated in colonic mucosal biopsies [62] as well as rectal NO levels were markedly enhanced in active ulcerative colitis and Crohn's disease [63]. Moreover, an increased number of mucosal nitrenergic nerve fibers was revealed in the duodenum, jejunum and descending colon of dogs with irritable bowel disease, and this increment was proportional to the state of the disease ranging from mild to severe [64].

3.4. Ischaemic Injuries

The deleterious effects of intestinal ischemia/reperfusion (I/R) injury on enteric neurons was also revealed in several studies. Alterations in neuronal structures or even neuronal loss were demonstrated in humans [65] and animal models [66,67] with I/R.

However, evidence showed that the NOS-containing enteric neuronal subpopulation is more susceptible to severe enteric neuropathies [5], like I/R, suggesting that NO from nitrenergic neurons contributes to neuronal damage. However, NO also has a neuroprotective effect: I/R resulted in more serious damage in nNOS knock out mice, than in their wild-type counterparts [68].

Swelling and distortion of nitrenergic neuronal dendrites and increased relative cell profile area of NOS neurons was observed following I/R in the ischaemic intestinal region [69–71]. Moreover, protein nitrosylation and translocation of Hu protein (enteric neuronal marker) from the cytoplasm to the nuclei was also demonstrated shortly after the onset of I/R [72].

4. Conclusions

Several studies have suggested that nitrenergic myenteric neurons are especially susceptible to the development of neuropathy in diseases of the digestive tract [5,27,28,34]. Although more than 20 years have passed since the biological properties of NO were discovered [73,74], many questions remain unanswered concerning the role of NO in neurons both in the gut and the brain [75]. To answer these questions, future studies will be required to investigate not only the ENS, but the microenvironment of the enteric ganglia, the microcirculation and neuro-immune interactions of the gut, the bidirectional communication in the gut–brain axis, and even the interactions among the microbiota, the GI tract and the brain in health and disease.

Author Contributions: Conceptualization, N.B. and M.B.; writing—original draft preparation, N.B. and M.B.; writing—review and editing, Z.S.; visualization, M.B. and N.B.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

AGE	advanced glycation end product
eNOS	endothelial nitric oxide synthase
ENS	enteric nervous system
GI	gastrointestinal

IBS	irritable bowel syndrome
iNOS	inducible nitric oxide synthase
I/R	ischemia/reperfusion
NANC	non-adrenergic, non-cholinergic
NO	nitric oxide
NOS	nitric oxide synthase
nNOS	neuronal nitric oxide synthase
VIP	vasoactive intestinal polypeptide

References

- Forstermann, U.; Sessa, W.C. Nitric oxide synthases: Regulation and function. *Eur. Heart J.* **2012**, *33*, 829–837. [[CrossRef](#)]
- Wallace, J.L. Nitric oxide in the gastrointestinal tract: Opportunities for drug development. *Br. J. Pharmacol.* **2019**, *176*, 147–154. [[CrossRef](#)]
- Bodi, N.; Battonyai, I.; Talapka, P.; Fekete, E.; Bagyanszki, M. Spatial pattern analysis of nitrergic neurons in the myenteric plexus of the duodenum of different mammalian species. *Acta Biol. Hung.* **2009**, *60*, 347–358. [[CrossRef](#)]
- Sanders, K.M.; Ward, S.M. Nitric oxide and its role as a non-adrenergic, non-cholinergic inhibitory neurotransmitter in the gastrointestinal tract. *Br. J. Pharmacol.* **2019**, *176*, 212–227. [[CrossRef](#)]
- Rivera, L.R.; Poole, D.P.; Thacker, M.; Furness, J.B. The involvement of nitric oxide synthase neurons in enteric neuropathies. *Neurogastroenterol. Motil.* **2011**, *23*, 980–988. [[CrossRef](#)] [[PubMed](#)]
- Furness, J.B. The organisation of the autonomic nervous system: Peripheral connections. *Auton Neurosci.* **2006**, *130*, 1–5. [[CrossRef](#)] [[PubMed](#)]
- Furness, J.B. The enteric nervous system and neurogastroenterology. *Nat. Rev. Gastroenterol. Hepatol.* **2012**, *9*, 286–294. [[CrossRef](#)] [[PubMed](#)]
- Lomax, A.E.; Linden, D.R.; Mawe, G.M.; Sharkey, K.A. Effects of gastrointestinal inflammation on enteroendocrine cells and enteric neural reflex circuits. *Auton Neurosci.* **2006**, *126–127*, 250–257. [[CrossRef](#)]
- Furness, J.B.; Callaghan, B.P.; Rivera, L.R.; Cho, H.J. The enteric nervous system and gastrointestinal innervation: Integrated local and central control. *Adv. Exp. Med. Biol.* **2014**, *817*, 39–71.
- Ma, Q.; Xing, C.; Long, W.; Wang, H.Y.; Liu, Q.; Wang, R.F. Impact of microbiota on central nervous system and neurological diseases: The gut-brain axis. *J. Neuroinflamm.* **2019**, *16*, 53. [[CrossRef](#)] [[PubMed](#)]
- Wirth, R.; Bodi, N.; Maroti, G.; Bagyanszki, M.; Talapka, P.; Fekete, E.; Bagi, Z.; Kovacs, K.L. Regionally distinct alterations in the composition of the gut microbiota in rats with streptozotocin-induced diabetes. *PLoS ONE* **2014**, *9*, e110440. [[CrossRef](#)]
- De Palma, G.; Collins, S.M.; Bercik, P.; Verdu, E.F. The microbiota-gut-brain axis in gastrointestinal disorders: Stressed bugs, stressed brain or both? *J. Physiol.* **2014**, *592*, 2989–2997. [[CrossRef](#)] [[PubMed](#)]
- Furness, J.B. Types of neurons in the enteric nervous system. *J. Auton Nerv. Syst.* **2000**, *81*, 87–96. [[CrossRef](#)]
- Qu, Z.D.; Thacker, M.; Castelucci, P.; Bagyanszki, M.; Epstein, M.L.; Furness, J.B. Immunohistochemical analysis of neuron types in the mouse small intestine. *Cell Tissue Res.* **2008**, *334*, 147–161. [[CrossRef](#)] [[PubMed](#)]
- Mittal, R.; Debs, L.H.; Patel, A.P.; Nguyen, D.; Patel, K.; O'Connor, G.; Grati, M.; Mittal, J.; Yan, D.; Eshraghi, A.A.; et al. Neurotransmitters: The Critical Modulators Regulating Gut-Brain Axis. *J. Cell Physiol.* **2017**, *232*, 2359–2372. [[CrossRef](#)] [[PubMed](#)]
- Lefebvre, R.A. Nitric oxide in the peripheral nervous system. *Ann. Med.* **1995**, *27*, 379–388. [[CrossRef](#)] [[PubMed](#)]
- Mizuta, Y.; Takahashi, T.; Owyang, C. Nitrergic regulation of colonic transit in rats. *Am. J. Physiol.* **1999**, *277*, G275–G279. [[CrossRef](#)]
- Bodi, N.; Jancso, Z.; Talapka, P.; Pal, A.; Poles, M.Z.; Bagyanszki, M.; Hermesz, E.; Fekete, E. Gut region-specific rearrangement of the cellular and subcellular compartments of nitric oxide synthase isoforms after chronic ethanol consumption in rats. *Histol. Histopathol.* **2014**, *29*, 1547–1555.
- Bredt, D.S.; Glatt, C.E.; Hwang, P.M.; Fotuhi, M.; Dawson, T.M.; Snyder, S.H. Nitric oxide synthase protein and mRNA are discretely localized in neuronal populations of the mammalian CNS together with NADPH diaphorase. *Neuron* **1991**, *7*, 615–624. [[CrossRef](#)]

20. Valentine, J.F.; Tannahill, C.L.; Stevenot, S.A.; Sallustio, J.E.; Nick, H.S.; Eaker, E.Y. Colitis and interleukin 1beta up-regulate inducible nitric oxide synthase and superoxide dismutase in rat myenteric neurons. *Gastroenterology* **1996**, *111*, 56–64. [[CrossRef](#)]
21. Vannucchi, M.G.; Corsani, L.; Bani, D.; Fausson-Pellegrini, M.S. Myenteric neurons and interstitial cells of Cajal of mouse colon express several nitric oxide synthase isoforms. *Neurosci. Lett.* **2002**, *326*, 191–195. [[CrossRef](#)]
22. Talapka, P.; Bodi, N.; Battonyai, I.; Fekete, E.; Bagyanszki, M. Subcellular distribution of nitric oxide synthase isoforms in the rat duodenum. *World J. Gastroenterol.* **2011**, *17*, 1026–1029. [[CrossRef](#)] [[PubMed](#)]
23. Bagyanszki, M.; Torfs, P.; Krecsmarik, M.; Fekete, E.; Adriaensen, D.; Van Nassauw, L.; Timmermans, J.P.; Kroese, A.B. Chronic alcohol consumption induces an overproduction of NO by nNOS- and iNOS-expressing myenteric neurons in the murine small intestine. *Neurogastroenterol. Motil.* **2011**, *23*, e237–e248. [[CrossRef](#)] [[PubMed](#)]
24. Mongardi Fantaguzzi, C.; Thacker, M.; Chiochetti, R.; Furness, J.B. Identification of neuron types in the submucosal ganglia of the mouse ileum. *Cell Tissue Res.* **2009**, *336*, 179–189. [[CrossRef](#)]
25. Noorian, A.R.; Taylor, G.M.; Annerino, D.M.; Greene, J.G. Neurochemical phenotypes of myenteric neurons in the rhesus monkey. *J. Comp. Neurol.* **2011**, *519*, 3387–3401. [[CrossRef](#)] [[PubMed](#)]
26. Celtek, S. Point of NO return for nitrergic nerves in diabetes: A new insight into diabetic complications. *Curr. Pharm. Des.* **2004**, *10*, 3683–3695. [[CrossRef](#)]
27. Izbeki, F.; Wittman, T.; Rosztoczy, A.; Linke, N.; Bodi, N.; Fekete, E.; Bagyanszki, M. Immediate insulin treatment prevents gut motility alterations and loss of nitrergic neurons in the ileum and colon of rats with streptozotocin-induced diabetes. *Diabetes Res. Clin. Pract.* **2008**, *80*, 192–198. [[CrossRef](#)] [[PubMed](#)]
28. Demedts, I.; Masaoka, T.; Kindt, S.; De Hertogh, G.; Geboes, K.; Farre, R.; Vanden Berghe, P.; Tack, J. Gastrointestinal motility changes and myenteric plexus alterations in spontaneously diabetic biobreeding rats. *J. Neurogastroenterol. Motil.* **2013**, *19*, 161–170. [[CrossRef](#)] [[PubMed](#)]
29. Watkins, C.C.; Sawa, A.; Jaffrey, S.; Blackshaw, S.; Barrow, R.K.; Snyder, S.H.; Ferris, C.D. Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy. *J. Clin. Investig.* **2000**, *106*, 803. [[CrossRef](#)]
30. Giancola, F.; Fracassi, F.; Gallucci, A.; Sadeghinezhad, J.; Polidoro, G.; Zini, E.; Asti, M.; Chiochetti, R. Quantification of nitrergic neurons in the myenteric plexus of gastric antrum and ileum of healthy and diabetic dogs. *Auton Neurosci.* **2016**, *197*, 25–33. [[CrossRef](#)]
31. Miller, S.M.; Narasimhan, R.A.; Schmalz, P.F.; Soffer, E.E.; Walsh, R.M.; Krishnamurthi, V.; Pasricha, P.J.; Szurszewski, J.H.; Farrugia, G. Distribution of interstitial cells of Cajal and nitrergic neurons in normal and diabetic human appendix. *Neurogastroenterol. Motil.* **2008**, *20*, 349–357. [[CrossRef](#)] [[PubMed](#)]
32. Zhang, C.M.; Huang, X.; Lu, H.L.; Meng, X.M.; Song, N.N.; Chen, L.; Kim, Y.C.; Chen, J.; Xu, W.X. Diabetes-induced damage of gastric nitric oxide neurons mediated by P2×7R in diabetic mice. *Eur. J. Pharmacol.* **2019**, *851*, 151–160. [[CrossRef](#)]
33. Yoneda, S.; Kadowaki, M.; Kuramoto, H.; Fukui, H.; Takaki, M. Enhanced colonic peristalsis by impairment of nitrergic enteric neurons in spontaneously diabetic rats. *Auton Neurosci.* **2001**, *92*, 65–71. [[CrossRef](#)]
34. Krecsmarik, M.; Izbeki, F.; Bagyanszki, M.; Linke, N.; Bodi, N.; Kaszaki, J.; Katarova, Z.; Szabo, A.; Fekete, E.; Wittmann, T. Chronic ethanol exposure impairs neuronal nitric oxide synthase in the rat intestine. *Alcohol Clin. Exp. Res.* **2006**, *30*, 967–973. [[CrossRef](#)] [[PubMed](#)]
35. Bodi, N.; Szalai, Z.; Chandrakumar, L.; Bagyanszki, M. Region-dependent effects of diabetes and insulin-replacement on neuronal nitric oxide synthase- and heme oxygenase-immunoreactive submucous neurons. *World J. Gastroenterol.* **2017**, *23*, 7359–7368. [[CrossRef](#)] [[PubMed](#)]
36. Bodi, N.; Talapka, P.; Poles, M.Z.; Hermes, E.; Jancso, Z.; Katarova, Z.; Izbeki, F.; Wittmann, T.; Fekete, E.; Bagyanszki, M. Gut region-specific diabetic damage to the capillary endothelium adjacent to the myenteric plexus. *Microcirculation* **2012**, *19*, 316–326. [[CrossRef](#)]
37. Bagyanszki, M.; Bodi, N. Diabetes-related alterations in the enteric nervous system and its microenvironment. *World J. Diabetes* **2012**, *3*, 80–93. [[CrossRef](#)] [[PubMed](#)]
38. Gangula, P.R.; Maner, W.L.; Micci, M.A.; Garfield, R.E.; Pasricha, P.J. Diabetes induces sex-dependent changes in neuronal nitric oxide synthase dimerization and function in the rat gastric antrum. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2007**, *292*, G725–G733. [[CrossRef](#)] [[PubMed](#)]

39. Gangula, P.R.; Mukhopadhyay, S.; Ravella, K.; Cai, S.; Channon, K.M.; Garfield, R.E.; Pasricha, P.J. Tetrahydrobiopterin (BH4), a cofactor for nNOS, restores gastric emptying and nNOS expression in female diabetic rats. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2010**, *298*, G692–G699. [[CrossRef](#)] [[PubMed](#)]
40. Celtek, S.; Foxwell, N.A.; Moncada, S. Two phases of nitrenergic neuropathy in streptozotocin-induced diabetic rats. *Diabetes* **2003**, *52*, 2353–2362. [[CrossRef](#)]
41. Celtek, S.; Qu, W.; Schmidt, A.M.; Moncada, S. Synergistic action of advanced glycation end products and endogenous nitric oxide leads to neuronal apoptosis in vitro: A new insight into selective nitrenergic neuropathy in diabetes. *Diabetologia* **2004**, *47*, 331–339. [[CrossRef](#)]
42. Korenaga, K.; Micci, M.A.; Tagliabata, G.; Pasricha, P.J. Suppression of nNOS expression in rat enteric neurones by the receptor for advanced glycation end-products. *Neurogastroenterol. Motil.* **2006**, *18*, 392–400. [[CrossRef](#)]
43. Jeyabal, P.V.; Kumar, R.; Gangula, P.R.; Micci, M.A.; Pasricha, P.J. Inhibitors of advanced glycation end-products prevent loss of enteric neuronal nitric oxide synthase in diabetic rats. *Neurogastroenterol. Motil.* **2008**, *20*, 253–261. [[CrossRef](#)] [[PubMed](#)]
44. Chandrakumar, L.; Bagyanszki, M.; Szalai, Z.; Mezei, D.; Bodi, N. Diabetes-Related Induction of the Heme Oxygenase System and Enhanced Colocalization of Heme Oxygenase 1 and 2 with Neuronal Nitric Oxide Synthase in Myenteric Neurons of Different Intestinal Segments. *Oxid. Med. Cell Longev.* **2017**, *2017*, 1890512. [[CrossRef](#)]
45. Shotton, H.R.; Lincoln, J. Diabetes only affects nitric oxide synthase-containing myenteric neurons that do not contain heme oxygenase 2. *Brain Res.* **2006**, *1068*, 248–256. [[CrossRef](#)] [[PubMed](#)]
46. Bagyanszki, M.; Bodi, N. Gut region-dependent alterations of nitrenergic myenteric neurons after chronic alcohol consumption. *World J. Gastrointest. Pathophysiol.* **2015**, *6*, 51–57. [[CrossRef](#)]
47. Bagyanszki, M.; Krecsmarik, M.; De Winter, B.Y.; De Man, J.G.; Fekete, E.; Pelckmans, P.A.; Adriaensen, D.; Kroese, A.B.; Van Nassauw, L.; Timmermans, J.P. Chronic alcohol consumption affects gastrointestinal motility and reduces the proportion of neuronal NOS-immunoreactive myenteric neurons in the murine jejunum. *Anat. Rec.* **2010**, *293*, 1536–1542. [[CrossRef](#)] [[PubMed](#)]
48. Bonthuis, D.J.; Bonthuis, N.E.; Li, S.; Karacay, B. The protective effect of neuronal nitric oxide synthase (nNOS) against alcohol toxicity depends upon the NO-cGMP-PKG pathway and NF-kappaB. *Neurotoxicology* **2008**, *29*, 1080–1091. [[CrossRef](#)]
49. Karacay, B.; Bonthuis, D.J. The neuronal nitric oxide synthase (nNOS) gene and neuroprotection against alcohol toxicity. *Cell Mol. Neurobiol.* **2015**, *35*, 449–461. [[CrossRef](#)]
50. Talapka, P.; Nagy, L.I.; Pal, A.; Poles, M.Z.; Berko, A.; Bagyanszki, M.; Puskas, L.G.; Fekete, E.; Bodi, N. Alleviated mucosal and neuronal damage in a rat model of Crohn's disease. *World J. Gastroenterol.* **2014**, *20*, 16690–16697. [[CrossRef](#)] [[PubMed](#)]
51. Marlow, S.L.; Blennerhassett, M.G. Deficient innervation characterizes intestinal strictures in a rat model of colitis. *Exp. Mol. Pathol.* **2006**, *80*, 54–66. [[CrossRef](#)]
52. Boyer, L.; Sidpra, D.; Jevon, G.; Buchan, A.M.; Jacobson, K. Differential responses of VIPergic and nitrenergic neurons in paediatric patients with Crohn's disease. *Auton Neurosci.* **2007**, *134*, 106–114. [[CrossRef](#)]
53. Winston, J.H.; Li, Q.; Sarna, S.K. Paradoxical regulation of ChAT and nNOS expression in animal models of Crohn's colitis and ulcerative colitis. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2013**, *305*, G295–G302. [[CrossRef](#)]
54. Li, S.; Fei, G.; Fang, X.; Yang, X.; Sun, X.; Qian, J.; Wood, J.D.; Ke, M. Changes in Enteric Neurons of Small Intestine in a Rat Model of Irritable Bowel Syndrome with Diarrhea. *J. Neurogastroenterol. Motil.* **2016**, *22*, 310–320. [[CrossRef](#)]
55. Rahman, A.A.; Robinson, A.M.; Jovanovska, V.; Eri, R.; Nurgali, K. Alterations in the distal colon innervation in Winnie mouse model of spontaneous chronic colitis. *Cell Tissue Res.* **2015**, *362*, 497–512. [[CrossRef](#)]
56. Schneider, J.; Jehle, E.C.; Starlinger, M.J.; Neunlist, M.; Michel, K.; Hoppe, S.; Schemann, M. Neurotransmitter coding of enteric neurones in the submucous plexus is changed in non-inflamed rectum of patients with Crohn's disease. *Neurogastroenterol. Motil.* **2001**, *13*, 255–264. [[CrossRef](#)]
57. de Fontgalland, D.; Brookes, S.J.; Gibbins, I.; Sia, T.C.; Wattchow, D.A. The neurochemical changes in the innervation of human colonic mesenteric and submucosal blood vessels in ulcerative colitis and Crohn's disease. *Neurogastroenterol. Motil.* **2014**, *26*, 731–744. [[CrossRef](#)]

58. Sanovic, S.; Lamb, D.P.; Blennerhassett, M.G. Damage to the enteric nervous system in experimental colitis. *Am. J. Pathol.* **1999**, *155*, 1051–1057. [[CrossRef](#)]
59. Venkataramana, S.; Lourenssen, S.; Miller, K.G.; Blennerhassett, M.G. Early inflammatory damage to intestinal neurons occurs via inducible nitric oxide synthase. *Neurobiol. Dis.* **2015**, *75*, 40–52. [[CrossRef](#)]
60. Turco, F.; Sarnelli, G.; Cirillo, C.; Palumbo, I.; De Giorgi, F.; D'Alessandro, A.; Cammarota, M.; Giuliano, M.; Cuomo, R. Enteroglial-derived S100B protein integrates bacteria-induced Toll-like receptor signalling in human enteric glial cells. *Gut* **2014**, *63*, 105–115. [[CrossRef](#)]
61. Brown, I.A.; McClain, J.L.; Watson, R.E.; Patel, B.A.; Gulbransen, B.D. Enteric glia mediate neuron death in colitis through purinergic pathways that require connexin-43 and nitric oxide. *Cell Mol. Gastroenterol. Hepatol.* **2016**, *2*, 77–91. [[CrossRef](#)]
62. Rachmilewitz, D.; Stampler, J.S.; Bachwich, D.; Karmeli, F.; Ackerman, Z.; Podolsky, D.K. Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn's disease. *Gut* **1995**, *36*, 718–723. [[CrossRef](#)]
63. Ljung, T.; Lundberg, S.; Varsanyi, M.; Johansson, C.; Schmidt, P.T.; Herulf, M.; Lundberg, J.O.; Hellstrom, P.M. Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: Responders versus nonresponders. *World J. Gastroenterol.* **2006**, *12*, 3386–3392. [[CrossRef](#)]
64. Rychlik, A.; Gonkowski, S.; Nowicki, M.; Calka, J. Inflammatory bowel disease affects density of nitrergic nerve fibers in the mucosal layer of the canine gastrointestinal tract. *Can. J. Vet. Res.* **2017**, *81*, 129–136.
65. Wedel, T.; Krammer, H.J.; Kuhnel, W.; Sigge, W. Alterations of the enteric nervous system in neonatal necrotizing enterocolitis revealed by whole-mount immunohistochemistry. *Pediatr. Pathol. Lab. Med.* **1998**, *18*, 57–70. [[CrossRef](#)]
66. Lindstrom, L.M.; Ekblad, E. Structural and neuronal changes in rat ileum after ischemia with reperfusion. *Dig. Dis. Sci.* **2004**, *49*, 1212–1222. [[CrossRef](#)]
67. Mei, F.; Guo, S.; He, Y.T.; Zhu, J.; Zhou, D.S.; Niu, J.Q.; Wang, H.Z.; Tian, Y.P. Apoptosis of interstitial cells of Cajal, smooth muscle cells, and enteric neurons induced by intestinal ischemia and reperfusion injury in adult guinea pigs. *Virchows Arch.* **2009**, *454*, 401–409. [[CrossRef](#)]
68. Rivera, L.R.; Pontell, L.; Cho, H.J.; Castelucci, P.; Thacker, M.; Poole, D.P.; Frugier, T.; Furness, J.B. Knock out of neuronal nitric oxide synthase exacerbates intestinal ischemia/reperfusion injury in mice. *Cell Tissue Res.* **2012**, *349*, 565–576. [[CrossRef](#)]
69. Rivera, L.R.; Thacker, M.; Castelucci, P.; Bron, R.; Furness, J.B. The reactions of specific neuron types to intestinal ischemia in the guinea pig enteric nervous system. *Acta Neuropathol.* **2009**, *118*, 261–270. [[CrossRef](#)]
70. da Silva de Souza, A.C.; Borges, S.C.; Beraldi, E.J.; de Sa-Nakanishi, A.B.; Comar, J.F.; Bracht, A.; Natali, M.R.; Buttow, N.C. Resveratrol Reduces Morphologic Changes in the Myenteric Plexus and Oxidative Stress in the Ileum in Rats with Ischemia/Reperfusion Injury. *Dig. Dis. Sci.* **2015**, *60*, 3252–3263. [[CrossRef](#)]
71. Marosti, A.R.; da Silva, M.V.; Palombit, K.; Mendes, C.E.; Tavares-de-Lima, W.; Castelucci, P. Differential effects of intestinal ischemia and reperfusion in rat enteric neurons and glial cells expressing P2 × 2 receptors. *Histol. Histopathol.* **2015**, *30*, 489–501. [[PubMed](#)]
72. Rivera, L.R.; Thacker, M.; Pontell, L.; Cho, H.J.; Furness, J.B. Deleterious effects of intestinal ischemia/reperfusion injury in the mouse enteric nervous system are associated with protein nitrosylation. *Cell Tissue Res.* **2011**, *344*, 111–123. [[CrossRef](#)] [[PubMed](#)]
73. Ignarro, L.J.; Buga, G.M.; Wood, K.S.; Byrns, R.E.; Chaudhuri, G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. *Proc. Natl. Acad. Sci. USA* **1987**, *84*, 9265–9269. [[CrossRef](#)] [[PubMed](#)]
74. Palmer, R.M.; Ferrige, A.G.; Moncada, S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. *Nature* **1987**, *327*, 524–526. [[CrossRef](#)] [[PubMed](#)]
75. Joca, S.R.L.; Sartim, A.G.; Roncalho, A.L.; Diniz, C.F.A.; Wegener, G. Nitric oxide signalling and antidepressant action revisited. *Cell Tissue Res.* **2019**. [[CrossRef](#)]

